Latest Breaking News On - Gabriele cerrone - Page 7 : comparemela.com

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

19.12.2023 - NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase . Seite 1

Gabriele cerroneMattheww davisTanuja chitnisTiziana life sciences ltdAccess programTiziana life sciencesProfessor of neurology at harvard medical schoolLife sciencesExpanded disability status scaleModified fatigue impact scalePrincipal investigatorMass general brigham healthcare systemHarvard medicalExpanded access programChief operating officerChief medical officer

4 new SPMS patients dosed with nasal foralumab outside of trials

4 new SPMS patients dosed with nasal foralumab outside of trials
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesGabriele cerroneAccess programTiziana life sciencesTiziana life

Tiziana Life Sciences : Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8 30am EST/ 1 30pm UK - Form 6-K -December 01, 2023 at 09:03 am EST

Tiziana Life Sciences Ltd Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8.30am EST/ 1.30pm UK TO BE HELD AS A REMOTE MEETING.

City ofUnited kingdomGabriele cerroneKeeren shahFounder of tiziana life sciencesFounder of contravir pharmaceuticals incSynergy pharmaceuticals incBristol myers squibb coFounder of rasna therapeuticsFermavir pharmaceuticals incTrovagene incCallisto pharmaceuticals incTiziana life sciences ltd the companySiga technologies incBiovitas capital ltdCompany auditors

Tiziana Life Sciences Ltd : Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

Tiziana Life Sciences Ltd : Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Gabriele cerronePaul spencerIrina kofflerStefan klotterLifesci advisorsTiziana life sciences ltdBusiness developmentTiziana life sciencesTea programAccess programBrigham healthcare system expanded access ea programTiziana life scienceConfirmatory evidenceTiziana lifeLife sciencesInvestor relations

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

NEW YORK, Nov. 30, 2023 Tiziana Life Sciences Ltd. , a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the.

Paul spencerIrina kofflerGabriele cerroneTiziana life sciences ltdGlobenewswire incLifesci advisorsTea programBrigham healthcare system expanded access ea programTiziana life sciencesBusiness developmentAccess programLife sciencesLife scienceConfirmatory evidenceInvestor relationsSci advisors